Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antonio Rivero

Showing results (1-10 of 382) with videos related to

Pageof 39
Sort By:
The Lancet. Infectious Diseases|January 25, 2016
Sustained virological response with sofosbuvir and ledipasvir for hepatitis C virus genotype 5Antonio Rivero-Juárez, Antonio Rivero
Expert Opinion on Drug Metabolism & Toxicology|May 26, 2015
Pharmacokinetic and pharmacodynamic evaluation of telaprevir for the treatment of hepatitis CAntonio Rivero-Juarez, Angela Camacho, Antonio Rivero
Revista Espanola De Enfermedades Digestivas|October 7, 2022
Orthohepevirus C as causal agent of acute hepatitis in SpainAntonio Rivero-Juárez, Mario Frías, Antonio Rivero
Expert Opinion on Biological Therapy|June 11, 2016
Current views on interferon therapy for HIVAntonio Rivero-Juárez, Mario Frias, Antonio Rivero
Expert Opinion on Drug Metabolism & Toxicology|February 7, 2017
Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infectionTeresa Brieva, Antonio Rivero, Antonio Rivero-Juarez
Enfermedades Infecciosas Y Microbiologia Clinica|November 15, 2011
[Does the cost of the drugs influence the choice of antiretroviral treatment regimens?]Antonio Rivero
Enfermedades Infecciosas Y Microbiologia Clinica|December 28, 2014
[In Process Citation]Antonio Rivero
Expert Opinion on Drug Metabolism & Toxicology|November 1, 2016
Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis CFrancisca Cuenca-Lopez, Antonio Rivero, Antonio Rivero-Juárez
Enfermedades Infecciosas Y Microbiologia Clinica|February 2, 2010
[Introduction. Usefulness of atazanavir in the treatment of patients infected by human immunodeficiency virus]Antonio Rivero
Expert Opinion on Drug Metabolism & Toxicology|July 31, 2018
Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis CAntonio Rivero-Juarez, Teresa Brieva, Mario Frias, et al.
Pageof 39

Showing results (1-10 of 382) with videos related to

Sort By:
Pageof 39
The Lancet. Infectious Diseases|January 25, 2016
Sustained virological response with sofosbuvir and ledipasvir for hepatitis C virus genotype 5Antonio Rivero-Juárez, Antonio Rivero
Expert Opinion on Drug Metabolism & Toxicology|May 26, 2015
Pharmacokinetic and pharmacodynamic evaluation of telaprevir for the treatment of hepatitis CAntonio Rivero-Juarez, Angela Camacho, Antonio Rivero
Revista Espanola De Enfermedades Digestivas|October 7, 2022
Orthohepevirus C as causal agent of acute hepatitis in SpainAntonio Rivero-Juárez, Mario Frías, Antonio Rivero
Expert Opinion on Biological Therapy|June 11, 2016
Current views on interferon therapy for HIVAntonio Rivero-Juárez, Mario Frias, Antonio Rivero
Expert Opinion on Drug Metabolism & Toxicology|February 7, 2017
Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infectionTeresa Brieva, Antonio Rivero, Antonio Rivero-Juarez
Enfermedades Infecciosas Y Microbiologia Clinica|November 15, 2011
[Does the cost of the drugs influence the choice of antiretroviral treatment regimens?]Antonio Rivero
Enfermedades Infecciosas Y Microbiologia Clinica|December 28, 2014
[In Process Citation]Antonio Rivero
Expert Opinion on Drug Metabolism & Toxicology|November 1, 2016
Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis CFrancisca Cuenca-Lopez, Antonio Rivero, Antonio Rivero-Juárez
Enfermedades Infecciosas Y Microbiologia Clinica|February 2, 2010
[Introduction. Usefulness of atazanavir in the treatment of patients infected by human immunodeficiency virus]Antonio Rivero
Expert Opinion on Drug Metabolism & Toxicology|July 31, 2018
Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis CAntonio Rivero-Juarez, Teresa Brieva, Mario Frias, et al.
Pageof 39